Microfluidic Purification of a Rare Antibody
March 27, 2018 | Terry Sharrer
This year’s flu season showed a weakness in preparation: vaccine manufacturers used an antibody for a narrow subset of the virus’ antigens. Consequently, the vaccine had only a10% effectiveness. A new approach takes a blood sample from people who are convalescing from influenza and runs the same through a microfluidics device to sort the HA subtypes. Then, high throughput screening and next generation sequencing could identify the most effective antibodies for a highly effective multivalent vaccine. MORE
image Credit: Wikimedia.commons